Drug intelligence / Profile preview

Elpida-03

Development stage: Preclinical
Lead developer: Elpida Therapeutics
Modality: AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies

Overview

Elpida-03 is a gene therapy candidate developed by Elpida Therapeutics, currently in preclinical development. It is being investigated for the treatment of telomere syndrome, a group of congenital disorders characterized by defects in telomere maintenance. The specific mechanism of action and molecular target for Elpida-03 have not been publicly disclosed as of June 2025. The therapy is part of Elpida Therapeutics' pipeline focused on addressing significant unmet medical needs in ultra-rare diseases, particularly those that have been deprioritized or overlooked by traditional biotech companies[1][4][9].

Beyond the preview

Go deeper on Elpida-03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elpida-03.

Explore the full profile